Enter your login e-mail to the account
Search
- Ocrelizumab – what we know, what we can improve now, what we can improve in the future
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Ofatumumab in clinical practice
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Laboratory biomarkers – neural antibodies in autoimmune diseases of the central nervous system
MUDr. Hana Mojžišová, MUDr. Martin Elišák, Ph.D., Prof. MUDr. Petr Marusič, Ph.D.
(3/2023, Main topic ) - B-cell targeted therapy to impact the progression of multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2023, Review articles ) - Autoimmune leukoencephalopatis with predominant brain involvement
MUDr. Martin Elišák, Ph.D., MUDr. Hana Mojžišová, doc. MUDr. Aleš Tomek, Ph.D., FESO
(3/2023, Main topic ) - Autoimmune meningoencephalitis associated with anti‑GFAP antibodies – a case study
MUDr. Hana Mojžišová, MUDr. Martin Elišák, Ph.D., RNDr. Jitka Hanzalová, MUDr. David Krýsl, Ph.D., Prof. MUDr. Petr Marusič, Ph.D.
(2/2023, Case reports ) - Autoimmune disease with positivity of anti‑CASPR2 antibodies – a case report
MUDr. Lubomír Jurák, Ph.D., MUDr. Zuzana Eichlová, MUDr. Eva Řeháčková, MUDr. Martin Jíra, MUDr. David Krýsl, Ph.D., MUDr. Martin Elišák, Ph.D., prof. MUDr. Petr Suchomel, Ph.D.
(1/2023, Case reports ) - Ocrelizumab – long-term efficacy and safety in real-world clinical practice in patients with relapsingremitting multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2022, Review articles ) - Management of secondary-progressive multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(1/2022, Review articles ) - Profile of a patient with secondary progressive MS – how to identify patients that should be sent to a tertiary Center
MUDr. Hana Mojžišová, MUDr. Martin Elišák, Ph.D.
(5/2021, Review articles ) - When to consider autoimmune etiology of central nervous system disorders in clinical practice
doc. MUDr. Petr Marusič, Ph.D., MUDr. Martin Elišák
(6/2015, Main topic )